Sigal Cusnir
CEO Starget Pharma
Seminars
Tuesday 11th November 2025
Lutetium 177 VS Terbium 161 – What are the Potentials for Next-Gen Radioisotopes?
3:30 pm
- Evaluating the differences in emission profiles, half-lives, and tissue penetration between 177Lu and 161Tb
- Assessing the potential of 161Tb to enhance tumour cell kill through higher linear energy transfer and Auger electron emission
- Discussing production, labelling, and regulatory considerations for integrating 161Tb into next-generation radiopharmaceuticals
